A heterotrimeric SMARCB1-SMARCC2 subcomplex is required for the assembly and tumor suppression function of the BAF chromatin-remodeling complex.
A heterotrimeric SMARCB1-SMARCC2 subcomplex is required for the assembly and tumor suppression function of the BAF chromatin-remodeling complex.
复制标题
BAF 染色质重塑复合物的组装和肿瘤抑制功能需要异三聚体 SMARCB1–SMARCC2 亚复合物
DOI:
10.1038/s41421-020-00196-4
复制
发表时间:
2020
期刊:
影响因子:
33.5
通讯作者:
Long J
中科院分区:
文献类型:
--
作者:
Chen G;Zhou H;Liu B;Wang Y;Zhao J;Giancotti FG;Long J
Dear Editor, The SWI/SNF complex utilizes its ATP-dependent chromatin-remodeling activity to mobilize nucleosomes and thus regulates DNA accessibility at nucleosomal templates. The BAF (mammalian SWI/SNF) complex is composed of approximately 15 protein subunits 1, 2. An important subcomplex of BAF consists of one of two mutually exclusive catalytic ATPase subunits (SMARCA2/Brm and SMARCA4/Brg1), SMARCB1/BAF47/INI1/SNF5, SMARCC1/BAF155, and SMARCC2/BAF170 3. Among them, SMARCC1 and SMARCC2 are highly similar to each other (Supplementary Fig. S1a) and considered as the key scaffold proteins in assembling and regulating the BAF 4, which are mutated in several cancers 2, 5. Intriguingly, SMARCB1 was found to be biallelically inactivated in~ 98% of all malignant rhabdoid tumors, aggressive pediatric tumors 6, 7. Recently, the cryo-electron microscopy (cryo-EM) structures of nucleosome bound-SWI/SNF,-RSC, or-BAF complexes were determined 8–10. However, the assembly and structure of subcomplexes Snf5-Swi3, SMARCB1-SMARCC2, and SFH1-RSC8 present in these articles are limited. Meantime, the mechanisms through which mutations in specific BAF subunits underlie the development of different cancer types are not well known.Firstly, we used a truncation-based approach to gradually map the minimal binding region of SMARCB1 and SMARCC2 (Supplementary Fig. S1b-g). We found that a region of SMARCB1 (aa 169–385, SMARCB1 (169–385)), and the SWIRM domain of SMARCC2 (aa 423–518, SMARCC2 (423–518))(Fig. 1 a) form a stable subcomplex (Supplementary Fig. S1g). We successfully crystallized a complex comprising a SMARCC2 fragment SMARCC2 (325–518) and SMARCB1 (169–385)(Fig. 1 a and Supplementary Fig. S1h). Finally, we determined the crystal structure of the human SMARCB1–SMARCC2 subcomplex at a resolution of 2.60 Å (Supplementary Table S1) and found that this subcomplex assembles into a heterotrimer (Fig. 1 b). Consistently, isothermal titration calorimetry (ITC) showed that SMARCC2 (325–518) binds to SMARCB1 (169–385) following a two-site binding model with two calculated Kd values (Supplementary Fig. S1i). In the final model, SMARCB1 (169-385) was resolved from aa 184 to aa 356 including the Rpt1 and Rpt2 motifs and SMARCC2 (325–518) was well resolved from 423 to 514 including the SWIRM domain (Fig. 1 b and Supplementary Fig. S2a-b). However, the N-terminal residues 325–422 of SMARCC2 (325–518) lacked observable density, possibly because they were degraded during crystallization (Supplementary Fig. S1j). Rpt1 (consisting of a two-stranded antiparallel β-sheet followed by two αhelices) and Rpt2 (consisting of a three-stranded antiparallel β-sheet and two α-helices) can be superimposed well with a root-mean-square deviation of 0.553 Å for 47 Cα atoms (Fig. 1 b and Supplementary Fig. S3a-b). Each Rpt motif binds to a separate SWIRM domain of SMARCC2 to form two separate subcomplexes (Fig. 1 b)(defined as Rpt1/SWIRM-1 and Rpt2/SWIRM-2). The